Expression of EZH2 and Paxillin in colorectal carcinoma and its relationship with clinical significance and prognosis

Abstract

Objective To study the relationship between of enhancer of zest homolog 2 (EZH2) and Paxillin with clinical and pathological characteristics in colorectal carcinoma.Methods Immunohistochemical method was used to assess the expression of EZH2 and Paxillin in 85 cases of human colorectal carcinoma tissues and non-cancerous adjacent colorectal tissues.Results The expression rate of EZH2 was 74.12％ (63/85) in colorectal carcinoma tissues,and 45.88％ (39/85) in non-cancerous adjacent colorectal tissues (P ＜0.01).The expression levels of EZH2 were related to histological grade,TNM stage and lymph node metastasis (P ＜ 0.05).The expression rate of Paxillin was 56.47％ (48/85) in colorectal carcinoma tissues,and 21.18％ (18/85) in non-cancerous adjacent colorectal tissues (P ＜ 0.01).There was a close relation between the expression of Paxillin and histological grade,serosa invasion,TNM stage and lymph node metastasis (P ＜ 0.05).Conclusion EZH2 and Paxillin may be used as markers for malignance degree and poor prognosis of colorectal carcinoma. Key words: Enhancer of zest homolog 2; Paxillin; Colorectal carcinoma